Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Chronic constipation (CC) and irritable bowel syndrome with constipation (IBS-C) are two functional gastrointestinal disorders that are associated with constipation. CC and IBS-C affect approximately 20% of the general population including the elderly, impairing quality of life. Patients not responding to over-the-counter treatments require effective and safe long-term therapies. Some treatments introduced in the last decade have been associated with side effects that led to withdrawal from the US market (e.g., tegaserod) or intolerance to treatment (e.g., nausea in patients treated with lubiprostone). Linaclotide is a novel drug, with a unique mechanism of action, low bioavailability and local action in the intestinal epithelial cells. It is currently being developed for patients with CC and IBS-C. From animal studies to human pharmacodynamic Phase Ib trials, and a comprehensive program of Phase IIb and III trials in health and disease, linaclotide demonstrates long-term efficacy and safety in CC and IBS-C.

Original languageEnglish (US)
Pages (from-to)301-310
Number of pages10
JournalExpert Review of Gastroenterology and Hepatology
Volume5
Issue number3
DOIs
StatePublished - Jun 2011

Fingerprint

Gastrointestinal Diseases
Guanylate Cyclase
Constipation
Irritable Bowel Syndrome
Therapeutics
Product Recalls and Withdrawals
linaclotide
Nausea
Biological Availability
Epithelial Cells
Quality of Life
Safety
Health
Pharmaceutical Preparations
Population

Keywords

  • constipation
  • guanylate cyclase C
  • guanylin
  • irritable bowel syndrome
  • linaclotide
  • uroguanylin

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

@article{bc998a20727b4a75bcc98b5899d156c6,
title = "Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation",
abstract = "Chronic constipation (CC) and irritable bowel syndrome with constipation (IBS-C) are two functional gastrointestinal disorders that are associated with constipation. CC and IBS-C affect approximately 20{\%} of the general population including the elderly, impairing quality of life. Patients not responding to over-the-counter treatments require effective and safe long-term therapies. Some treatments introduced in the last decade have been associated with side effects that led to withdrawal from the US market (e.g., tegaserod) or intolerance to treatment (e.g., nausea in patients treated with lubiprostone). Linaclotide is a novel drug, with a unique mechanism of action, low bioavailability and local action in the intestinal epithelial cells. It is currently being developed for patients with CC and IBS-C. From animal studies to human pharmacodynamic Phase Ib trials, and a comprehensive program of Phase IIb and III trials in health and disease, linaclotide demonstrates long-term efficacy and safety in CC and IBS-C.",
keywords = "constipation, guanylate cyclase C, guanylin, irritable bowel syndrome, linaclotide, uroguanylin",
author = "{Vazquez Roque}, {Maria I} and Michael Camilleri",
year = "2011",
month = "6",
doi = "10.1586/egh.11.30",
language = "English (US)",
volume = "5",
pages = "301--310",
journal = "Expert Review of Gastroenterology and Hepatology",
issn = "1747-4124",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation

AU - Vazquez Roque, Maria I

AU - Camilleri, Michael

PY - 2011/6

Y1 - 2011/6

N2 - Chronic constipation (CC) and irritable bowel syndrome with constipation (IBS-C) are two functional gastrointestinal disorders that are associated with constipation. CC and IBS-C affect approximately 20% of the general population including the elderly, impairing quality of life. Patients not responding to over-the-counter treatments require effective and safe long-term therapies. Some treatments introduced in the last decade have been associated with side effects that led to withdrawal from the US market (e.g., tegaserod) or intolerance to treatment (e.g., nausea in patients treated with lubiprostone). Linaclotide is a novel drug, with a unique mechanism of action, low bioavailability and local action in the intestinal epithelial cells. It is currently being developed for patients with CC and IBS-C. From animal studies to human pharmacodynamic Phase Ib trials, and a comprehensive program of Phase IIb and III trials in health and disease, linaclotide demonstrates long-term efficacy and safety in CC and IBS-C.

AB - Chronic constipation (CC) and irritable bowel syndrome with constipation (IBS-C) are two functional gastrointestinal disorders that are associated with constipation. CC and IBS-C affect approximately 20% of the general population including the elderly, impairing quality of life. Patients not responding to over-the-counter treatments require effective and safe long-term therapies. Some treatments introduced in the last decade have been associated with side effects that led to withdrawal from the US market (e.g., tegaserod) or intolerance to treatment (e.g., nausea in patients treated with lubiprostone). Linaclotide is a novel drug, with a unique mechanism of action, low bioavailability and local action in the intestinal epithelial cells. It is currently being developed for patients with CC and IBS-C. From animal studies to human pharmacodynamic Phase Ib trials, and a comprehensive program of Phase IIb and III trials in health and disease, linaclotide demonstrates long-term efficacy and safety in CC and IBS-C.

KW - constipation

KW - guanylate cyclase C

KW - guanylin

KW - irritable bowel syndrome

KW - linaclotide

KW - uroguanylin

UR - http://www.scopus.com/inward/record.url?scp=79958248056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958248056&partnerID=8YFLogxK

U2 - 10.1586/egh.11.30

DO - 10.1586/egh.11.30

M3 - Article

VL - 5

SP - 301

EP - 310

JO - Expert Review of Gastroenterology and Hepatology

JF - Expert Review of Gastroenterology and Hepatology

SN - 1747-4124

IS - 3

ER -